Roxarel10 mg

Roxarel 10 mg is a direct-acting oral anticoagulant (a Factor Xa inhibitor) approved for the following indications:

FDA-approved indications

• Reduction of risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
• Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Reduction in the risk of recurrence of DVT and/or PE following at least 6 months of initial anticoagulant treatment.
• Prophylaxis of DVT, which may lead to PE, in patients undergoing hip or knee replacement surgery.
• Prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients at risk for thromboembolic complications who are not at high bleeding risk.
• In combination with low-dose aspirin, reduction of risk of major cardiovascular events (cardiovascular death, myocardial infarction, stroke) in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).

Pediatric indications

• Treatment of VTE and reduction in risk of recurrent VTE in pediatric patients from birth to less than 18 years of age, after at least 5 days of initial parenteral anticoagulation.
• Thromboprophylaxis in pediatric patients 2 years of age and older after the Fontan procedure.

Use of Roxarel 10 mg for any indication should be guided by a qualified physician based on individual risk assessment.

Each film-coated tablet contains Roxarel 10 mg INN as the active ingredient, commonly available in strengths of 2.5 mg, 10 mg, 15 mg, and 20 mg. Tablets also contain standard pharmaceutical excipients such as microcrystalline cellulose, croscarmellose sodium, lactose monohydrate, hypromellose, sodium lauryl sulfate, magnesium stearate, and film-coating agents.

Roxarel 10 mg is an orally administered, direct-acting inhibitor of activated Factor X (Factor Xa), a key enzyme in the blood coagulation cascade. Unlike vitamin K antagonists such as warfarin, Roxarel 10 mg has a predictable anticoagulant effect, a rapid onset of action, fewer food and drug interactions, and does not require routine coagulation monitoring. It is widely used for the prevention and treatment of thromboembolic disorders, including stroke prevention in atrial fibrillation and treatment/prevention of venous thromboembolism.

Roxarel 10 mg belongs to the class of Direct Oral Anticoagulants (DOACs), specifically the Factor Xa inhibitors. It is classified therapeutically as an antithrombotic/anticoagulant agent.

Mechanism of Action

Roxarel 10 mg is a selective, direct inhibitor of Factor Xa. By inhibiting Factor Xa, Roxarel 10 mg interrupts the intrinsic and extrinsic pathways of the coagulation cascade, preventing thrombin generation and thrombus formation, without directly inhibiting thrombin (Factor IIa) or requiring antithrombin as a cofactor.

Pharmacokinetics

• Absorption: Rapidly absorbed with high oral bioavailability (approximately 80-100% for the 10 mg dose); higher doses (15 mg, 20 mg) should be taken with food to maximize absorption.
• Protein binding: Approximately 92-95% bound to plasma proteins, mainly albumin.
• Metabolism: Metabolized in the liver via CYP3A4, CYP2J2, and CYP-independent mechanisms; it is also a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) transporters.
• Elimination: Approximately one-third excreted unchanged in urine (active renal secretion); the remainder eliminated as metabolites in urine and feces. Terminal half-life is approximately 5-9 hours in healthy young adults and 11-13 hours in elderly patients.

Roxarel 10 mg tablets should be swallowed whole with water. The 15 mg and 20 mg doses must be taken with food to ensure optimal absorption; the 10 mg and 2.5 mg doses may be taken with or without food.

Patients unable to swallow whole tablets may, for certain strengths, have the tablet crushed and mixed with soft food (such as applesauce) or suspended in water and administered orally or via nasogastric tube, immediately followed by food, only as advised by a physician — never alter the dosage form without medical guidance.

Roxarel 10 mg should be taken at approximately the same time each day. Do not stop taking Roxarel 10 mg without first talking to the prescribing physician, as premature discontinuation increases the risk of thrombotic events (see Precautions and Warnings).

Clinically Significant Drug Interactions

Concomitant use of Roxarel 10 mg with the following agents should be avoided or requires caution, as they significantly affect Roxarel 10 mg exposure through CYP3A4 and P-glycoprotein (P-gp) pathways, or additively increase bleeding risk:

• Combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, lopinavir/ritonavir, clarithromycin): increase Roxarel 10 mg plasma concentration and bleeding risk — avoid combination.
• Combined P-gp and strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort): reduce Roxarel 10 mg plasma concentration and efficacy, increasing risk of thrombosis — avoid combination.
• Other anticoagulants (warfarin, heparins, other DOACs, fondaparinux): additive bleeding risk with Roxarel 10 mg — avoid concurrent use except during controlled transition periods.
• Antiplatelet agents and NSAIDs (aspirin, clopidogrel and other P2Y12 inhibitors, chronic NSAID use): increase bleeding risk when combined with Roxarel 10 mg — use with caution and only when clinically indicated (aspirin is used deliberately in the CAD/PAD indication).
• SSRIs/SNRIs: may increase bleeding risk when combined with Roxarel 10 mg.

Always inform the prescribing physician and pharmacist about all medicines, supplements, and herbal products being taken before starting Roxarel 10 mg.

Most Common

• Bleeding (the most common adverse reaction overall) — may present as bruising, nosebleeds, gum bleeding, blood in urine or stool, or heavier menstrual bleeding.
• Nausea
• Elevated liver enzymes (transaminases)

Serious/Less Common

• Major bleeding, including gastrointestinal hemorrhage and intracranial hemorrhage
• Epidural or spinal hematoma in patients undergoing neuraxial anesthesia or spinal puncture (see Precautions and Warnings)
• Hypersensitivity reactions, including rash, pruritus, and rarely angioedema or anaphylaxis
• Anemia

Patients taking Roxarel 10 mg should seek immediate medical attention for signs of serious bleeding (unusual bruising, pink/brown urine, red/black stools, coughing or vomiting blood, severe headache, dizziness, or weakness).

Pregnancy

Roxarel 10 mg is generally not recommended during pregnancy because adequate anticoagulant effect cannot be monitored with standard coagulation tests, and it may carry a risk of bleeding in the mother and fetus/neonate, as well as potential fetal harm based on its mechanism of action. Roxarel 10 mg should be used during pregnancy only if the potential benefit clearly justifies the potential risk to the mother and fetus, and only under close physician supervision. Women of childbearing potential should discuss pregnancy planning with their physician while on Roxarel 10 mg.

Lactation

It is not known whether Roxarel 10 mg is excreted in human breast milk in clinically significant amounts; limited data suggest some transfer into breast milk. Because of the potential for serious adverse reactions, including bleeding, in a breastfed infant, a decision should be made to discontinue breastfeeding or discontinue Roxarel 10 mg, taking into account the importance of the drug to the mother — consult a physician before use while breastfeeding.

Boxed Warnings

• Risk of thrombotic events after premature discontinuation: Stopping Roxarel 10 mg abruptly, other than for active bleeding or completion of a course of therapy, increases the risk of stroke and other thrombotic events, particularly in patients with atrial fibrillation. If Roxarel 10 mg must be discontinued for a reason other than pathological bleeding, coverage with an alternative anticoagulant should be considered as directed by the treating physician. Do not stop Roxarel 10 mg without first consulting the prescribing physician.
• Spinal/epidural hematoma: Patients on Roxarel 10 mg who receive neuraxial anesthesia (spinal/epidural) or undergo spinal puncture are at risk of developing an epidural or spinal hematoma, which can result in long-term or permanent paralysis. This risk is increased by indwelling epidural catheters, concomitant use of other drugs affecting hemostasis (NSAIDs, platelet inhibitors, other anticoagulants), a history of traumatic or repeated epidural/spinal puncture, and a history of spinal deformity or spinal surgery. Careful timing of Roxarel 10 mg doses relative to neuraxial procedures, as determined by the physician/anesthesiologist, is essential, and patients should be monitored for signs of neurological impairment after such procedures.

Bleeding Risk

Roxarel 10 mg, like all anticoagulants, increases the risk of bleeding, which can be serious and, rarely, fatal. Promptly evaluate any signs or symptoms of blood loss. There is no routinely available reversal agent in many settings; management of serious bleeding may require specialist consultation and supportive measures.

Procedures and Surgery

Roxarel 10 mg should generally be discontinued at least 24 hours before elective surgery or invasive procedures with a moderate-to-high bleeding risk, and restarted only once adequate hemostasis has been achieved, as determined by the treating physician. Patients must inform all healthcare providers, including surgeons and dentists, that they are taking Roxarel 10 mg before any procedure.

No Routine Coagulation Monitoring

Unlike warfarin, Roxarel 10 mg does not require routine coagulation monitoring (e.g., INR) under normal circumstances, but renal and hepatic function should be assessed before starting therapy and periodically thereafter.

Antiphospholipid Syndrome

Roxarel 10 mg is not recommended in patients with triple-positive antiphospholipid syndrome due to a possible increased risk of recurrent thrombotic events.

For contraindications, see the Contraindications section; for pregnancy/lactation guidance, see Pregnancy and Lactation.

Overdose of Roxarel 10 mg may result in excessive bleeding due to its anticoagulant effect. Signs of overdose may include unusual bruising, prolonged bleeding from cuts, blood in urine or stool, or symptoms of internal bleeding such as severe headache, dizziness, or weakness. There is no specific reversal agent widely available in routine clinical practice for most bleeding events, and due to high protein binding, Roxarel 10 mg is not significantly removed by dialysis. In case of suspected overdose or serious bleeding with Roxarel 10 mg, seek immediate medical attention or contact a hospital emergency department/poison control center without delay. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

Dose adjustment of Roxarel 10 mg is required in several indications based on creatinine clearance (see Dosage and Administration). Use is generally avoided in severe renal impairment (CrCl <15 mL/min) due to insufficient clinical data. Renal function should be monitored periodically, especially in elderly patients or those with declining renal function.

Hepatic Impairment

Roxarel 10 mg is not recommended in moderate-to-severe hepatic impairment (Child-Pugh B or C) or in any hepatic disease associated with coagulopathy.

Elderly

No dose adjustment of Roxarel 10 mg is required based on age alone, but elderly patients may have reduced renal function and should be monitored closely for bleeding.

Body Weight

Extremes of body weight (very low or very high) may affect drug exposure; use Roxarel 10 mg with caution and clinical monitoring in such patients.

See also Pediatric Uses and Pregnancy and Lactation sections.

Duration of Roxarel 10 mg therapy is individualized based on indication: DVT/PE treatment typically requires at least 3 months (21 days at the higher treatment dose followed by the maintenance dose), with longer or extended therapy for recurrence prevention as determined by the physician. Stroke prevention in atrial fibrillation is typically long-term/indefinite, guided by ongoing risk assessment. Post-surgical VTE prophylaxis is short-term (12-35 days depending on the procedure). The treating physician determines the appropriate duration of Roxarel 10 mg based on the underlying condition, bleeding risk, and response to therapy; Roxarel 10 mg should not be stopped early without medical advice (see Precautions and Warnings).

Most Roxarel 10 mg tablet formulations do not require reconstitution. However, the pediatric oral suspension formulation of Roxarel 10 mg (granules for oral suspension) must be reconstituted with water by a pharmacist or caregiver according to the manufacturer's instructions before use, producing a 1 mg/mL suspension. Once reconstituted, the suspension should be stored at room temperature, used within the manufacturer-specified period (typically up to 60 days), and shaken well before each dose. This formulation may not be widely available in all markets; consult your pharmacist for local availability.

Roxarel 10 mg belongs to the Direct Oral Anticoagulants (DOACs) / Factor Xa Inhibitors drug class, also referred to as non-vitamin K antagonist oral anticoagulants (NOACs).

Roxarel 10 mg works by selectively and directly inhibiting Factor Xa, a central enzyme in both the intrinsic and extrinsic coagulation pathways. By blocking Factor Xa, Roxarel 10 mg prevents the conversion of prothrombin to thrombin, thereby reducing thrombin generation and inhibiting the formation of fibrin clots, without requiring antithrombin as a cofactor.

Roxarel 10 mg is approved for use in pediatric patients for specific indications, with dosing based on body weight and formulation (oral suspension or tablets):

• Treatment of venous thromboembolism (VTE) and reduction in risk of VTE recurrence in pediatric patients from birth to less than 18 years of age, following at least 5 days of initial treatment with a parenteral anticoagulant.
• Thromboprophylaxis in pediatric patients 2 years of age and older who have undergone the Fontan procedure.

Safety and efficacy of Roxarel 10 mg have not been established for other pediatric indications or in preterm neonates. Pediatric dosing of Roxarel 10 mg must be individualized and supervised by a specialist physician, with careful attention to renal function and body weight.